Evidence map›Paper›PMID 37177365›Full record

ReviewPolymers2023

Design and Application of Hybrid Polymer-Protein Systems in Cancer Therapy.

Qi Sun, Zhenzhen Yang, Xianrong Qi

Abstract readReview
In one paragraph

Review in Polymers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Editorial: Biomaterials and biologicals for disease treatment.Frontiers in bioengineering and biotechnology · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Qi SunDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.ORCID 0009-0005-9117-9134
Zhenzhen YangDrug Clinical Trial Center, Peking University Third Hospital, Peking University, Beijing 100191, China.
Xianrong QiDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.ORCID 0000-0002-8264-0794

Funding

Beijing Natural Science Foundation No. L2020440National Natural Science Foundation of China No. 81973258/No. 81803459R&D Program of Beijing Municipal Education Commission KM202310025023
6 · The paper itself

Abstract

Polymer-protein systems have excellent characteristics, such as non-toxic, non-irritating, good water solubility and biocompatibility, which makes them very appealing as cancer therapeutics agents. Inspiringly, they can achieve sustained release and targeted delivery of drugs, greatly improving the effect of cancer therapy and reducing side effects. However, many challenges, such as reducing the toxicity of materials, protecting the activities of proteins and controlling the release of proteins, still need to be overcome. In this review, the design of hybrid polymer-protein systems, including the selection of polymers and the bonding forms of polymer-protein systems, is presented. Meanwhile, vital considerations, including reaction conditions and the release of proteins in the design process, are addressed. Then, hybrid polymer-protein systems developed in the past decades for cancer therapy, including targeted therapy, gene therapy, phototherapy, immunotherapy and vaccine therapy, are summarized. Furthermore, challenges for the hybrid polymer-protein systems in cancer therapy are exemplified, and the perspectives of the field are covered.

Indexed as

applicationcancer therapydesignpolymerprotein

Identifiers

PMID37177365
PMCPMC10181109

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.